Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481S |
| Therapy | Ibrutinib |
| Indication/Tumor Type | diffuse large B-cell lymphoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK C481S demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 35196427). | 35196427 |
| BTK C481S | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK C481S was resistant to Imbruvica (ibrutinib) treatment in culture (PMID: 29875397). | 29875397 |
| BTK C481S | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK C481S demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 38301010). | 38301010 |
| BTK C481S | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, diffuse large B-cell lymphoma cell lines expressing BTK C481S demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 36183831). | 36183831 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35196427) | Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. | Full reference... |
| (36183831) | BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma. | Full reference... |
| (38301010) | Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. | Full reference... |
| (29875397) | PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. | Full reference... |